Represents the period until which FDA approval will be stayed from the date of receipt of notice.

No definition available.

Name:	depo_GainContingencyPeriodOfStayOnFDAApproval
Namespace Prefix:	depo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of shareholder derivative actions that were filed.

+ References

No definition available.

+ Details

Name:	depo_NumberOfShareholderDerivativeActionsFiled
Namespace Prefix:	depo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the period of regulatory exclusivity of marketing a product.

+ References

No definition available.

+ Details

Name:	depo_PeriodOfRegulatoryExclusivityForMarketingProduct
Namespace Prefix:	depo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of defendants named in a legal action.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyNumberOfDefendants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_LitigationCaseAxis=depo_CollectivelyActavisCollectivelyWatsonAndInceptaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=depo_OneHundredThirtyPatentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=depo_StridesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=depo_BannerAndWatsonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=depo_ZipsorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=depo_InformationOnFirstPlaceOfActionFiledMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COMMITMENTS AND CONTINGENCIES - LEGAL MATTERS (Details)				1 Months Ended	6 Months Ended	9 Months Ended
COMMITMENTS AND CONTINGENCIES - LEGAL MATTERS (Details)	Nov. 15, 2017 action	May 05, 2017	Apr. 11, 2017 defendant patent	Feb. 29, 2016 patent	Dec. 31, 2017 action	Sep. 30, 2017
Legal matters
Number of shareholder derivative actions filed \| action					3
Gralise ANDA Filers
Legal matters
Number of patents infringed \| patent			3	3
Number of defendants \| defendant			3
130 Patent
Legal matters
Number of defendants \| defendant			4
Strides
Legal matters
Period of stay for FDA approval		30 months
Banner and Watson \| Zipsor
Legal matters
Eligible period of regulatory exclusivity						180 days
Northern District of California
Legal matters
Number of shareholder derivative actions filed \| action	2